Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.54 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23248565 | 0.90 | EGFR (0.49) | EGFRIGF1RKCNH2 | |
| SCHEMBL23248562 | 0.88 | EGFR (0.49) | EGFR | |
| SCHEMBL31348830 | 0.85 | EGFR (0.53) | EGFRUCHL3IGF1RKCNH2 | |
| SCHEMBL16385655 | 0.85 | EGFR (0.53) | EGFRUCHL3IGF1RKCNH2 | |
| SCHEMBL23248721 | 0.85 | EGFR (0.57) | EGFR | |
| SCHEMBL24726489 | 0.84 | EGFR (0.54) | EGFRUCHL3IGF1RKCNH2 | |
| SCHEMBL21816616 | 0.82 | EGFR (0.59) | EGFRUCHL3IGF1RKCNH2 | |
| SCHEMBL21816647 | 0.81 | EGFR (0.41) | EGFRUCHL3 | |
| SCHEMBL23983216 | 0.80 | EGFR (0.55) | EGFRIGF1RKCNH2 | |
| SCHEMBL16385654 | 0.80 | EGFR (0.50) | EGFRUCHL3IGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| WO-2021075691-A1 | PYRIMIDINE DERIVATIVE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME AS EFFECTIVE COMPONENT | 한국화학연구원 | 2021-04-22 | — | — | WO | disclosed |
| CN-108707139-B | Aminopyrimidine compound and preparation method and application thereof | 北京鞍石生物科技有限责任公司 | 2021-04-06 | — | — | CN | disclosed |
| EP-3640248-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-04-22 | — | — | EP | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | EGFR 3/4885UCHL3 3225/4885IGF1R 342/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | EGFR 3/4885UCHL3 3225/4885IGF1R 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.